8 completed, 4 not yet recruiting, 2 unknown, 1 no longer available. 4 Phase 3, 4 Phase 4, 3 Phase 1, 3 Phase 2, 1 Not applicable.
Follow Pseudomonas Aeruginosa Infection: new trials by email Literature Review of Pseudomonas Aeruginosa Infection trials Research Report on Pseudomonas Aeruginosa Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Study of Nebulized Bacteriophages in Patients With Ventilator-Associated Pneumonia Due to Pseudomonas Aeruginosa Bacteriophages GMP, saline solution (placebo) - Ventilator Associated Bacterial Pneumonia, Pseudomonas Aeruginosa Infection | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 184 | 2026-11-03 | 2026-09-04 |
| Early Optimization of Ceftazidime Regimen in Critical Care ceftazidime, plasma ceftazidime dosage - Infection in ICU, Sepsis | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 128 | 2026-10-01 | 2026-09-16 |
| MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia MP101, Antibiotics - Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection | Phase 1 | Recruiting | MicrobiotiX Co., Ltd | 18 | 2026-07-25 | 2026-07-28 |
| Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance - Hematologic Neoplasms, Gram-Negative Bacterial Infections | Not yet recruiting | Sizhou Feng | 60 | 2026-07-09 | 2026-07-14 | |
| Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection bronchoscopy - Rapid Detection, Pseudomonas Aeruginosa Infection | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 100 | 2025-09-01 | 2025-08-14 | |
| Development and Validation of (Bio)Sensors for the Identification of Pathogens Nanobiotechnology platforms - Infections, Infection, Bacterial | Completed | University of Bologna | 149 | 2024-05-30 | 2025-12-10 | |
| Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals Pseudomonas Aeruginosa Infection | Unknown | Sohag University | 100 | 2024-04-01 | 2024-05-20 | |
| Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® IMP, Placebo - Surgical Site Infection, Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Unknown | MB PHARMA s.r.o. | 52 | 2023-10-27 | 2024-03-19 |
| Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis Tobramycin Inhalant Product, Ciprofloxacin 750 MG, Oral ciprofloxacin placebo - Bronchiectasis Adult, Pseudomonas Aeruginosa Infection | Phase 4 | Completed | Jin-Fu Xu | 371 | 2023-10-18 | 2026-04-17 |
| Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Ceftolozane / Tazobactam Injection - Pneumonia, Hematologic Malignancy | Phase 4 | Terminated | Weill Medical College of Cornell University | 17 | 2023-01-10 | 2026-01-21 |
| Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers TP-102 - Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection | Phase 1 / Phase 2 | Completed | Technophage, SA | 20 | 2021-03-22 | 2022-10-04 |
| Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Ceftolozane/Tazobactam - Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation | Phase 4 | Completed | Joseph L. Kuti, PharmD | 21 | 2015-09-01 | 2020-08-04 |
| Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 IC43, Placebo - Pseudomonas Aeruginosa Infection | Phase 2 / Phase 3 | Completed | Valneva Austria GmbH | 803 | 2012-03-01 | 2016-03-31 |
| Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer., Tobramycin inhalation solution using a PARI LC® Plus nebulizer. - Pseudomonas Aeruginosa Infection | Phase 3 | Completed | Insmed Incorporated | 302 | 2012-02-29 | 2020-06-16 |
| Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children meropenem - Cystic Fibrosis, Pneumonia | Phase 4 | Completed | Joseph Kuti | 30 | 2012-02-01 | 2018-03-20 |
| Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa Piperacillin-Tazobactam continuous infusion, Piperacillin-Tazobactam intermittent infusion - Pseudomonas Aeruginosa Infection | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 76 | 2011-05-01 | 2014-09-22 |
| Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia Phage Therapy - Covid19, Bacteremia | No longer available | Adaptive Phage Therapeutics, Inc. | 2021-12-21 |
Pseudomonas Infections (17) · Cystic Fibrosis (3) · Staphylococcal Infections (3) · Bacteremia (2) · Bacterial Infections (2) · COVID-19 (2) · Gram-Negative Bacterial Infections (2) · Hematologic Neoplasms (2) · Infections (2) · Pneumonia (2) · Sepsis (2) · Acinetobacter Infections (1) · Bronchiectasis (1) · Diabetic Foot (1) · Disease (1)
Bacterial Infections and Mycoses (17) · Bacterial Infections (15) · Gram-Negative Bacterial Infections (15) · Infections (15) · Respiratory Tract Diseases (8) · Lung Diseases (7) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Respiratory Tract Infections (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Digestive System Diseases (3) · Genetic Diseases, Inborn (3) · Gram-Positive Bacterial Infections (3) · Infant, Newborn, Diseases (3) · Inflammation (3)
Anti-Bacterial Agents (2) · ceftolozane, tazobactam drug combination (2) · Bronchoscopy (1) · Ceftazidime (1) · Ciprofloxacin (1) · Inhalation (1) · Inosine Monophosphate (1) · Meropenem (1) · Nebulizers and Vaporizers (1) · Phage Therapy (1) · Saline Solution (1) · Sodium Chloride (1) · avibactam, ceftazidime drug combination (1) · ceftolozane (1)
Adaptive Phage Therapeutics, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Insmed Incorporated (1) · Jin-Fu Xu (1) · Joseph Kuti (1) · Joseph L. Kuti, PharmD (1) · MB PHARMA s.r.o. (1) · MicrobiotiX Co., Ltd (1) · Sizhou Feng (1) · Sohag University (1) · Technophage, SA (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Bologna (1)
China (3) · France (3) · Spain (3) · United States (3) · Austria (2) · Belgium (2) · Czechia (2) · Germany (2) · Hungary (2) · Italy (2) · Bulgaria (1) · Canada (1) · Denmark (1) · Egypt (1) · Greece (1)
Gina Eagle, MD (1) · Jin-Fu Xu, MD, PhD (1) · Joseph L Kuti, Pharm.D. (1) · Joseph L Kuti, PharmD (1) · Jun Yong Choi (1) · Markus Plate, MD (1) · Ran Nir-Paz, MD (1) · Robert Staffa, prof. (1) · Ronen Ben Ami, MD (1) · Sizhou Feng, MD (1) · Susanne Eder, Mag (1) · Tiziana Lazzarotto, PhD (1)
PMID 26416780, PMID 27550351, PMID 31451351, PMID 32131866, PMID 39740667